CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas. - Babin L; Andraos E; Fuchs S; Bessière C; Colras L; Dailhau S; Quelen C; Pinto C; Daoudi I; Pfeifer R; Zamani A; Bousquet M; et al. (Leukemia, 2026)